Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
DoD Peer Reviewed Cancer, Behavioral Health Science Award
The Behavioral Health Science Award supports innovative research and high-reward studies that span the spectrum of behavioral health science, including quality of life, symptom management, resilience, neurocognitive deficits, and psychosocial issues related to cancer diagnosis, treatment, and survivorship.
Studies
must address one or more of these critical issues in at least one of the FY22 PRCRP Topic Areas.
The overall intention of the Behavioral Health Science Award is to advance behavioral health cancer science and fill gaps in the understanding of survivorship, including investigations into the psychological health and well-being of those affected by cancer (e.g., patients, family members).
This may include investigations into studies that improve mental health and/or cancer-related outcomes in defined populations.
Studies also may assess the relationship(s) between behavioral and social functioning in relation to cancer initiation, progression, detection, treatment, and rehabilitation.
Applications may propose behavioral science that examines quality-of-life studies, decision-making and/or cognitive function research, development and testing of educational interventions, and symptom management (e.g., toxicity of treatment, palliative care, psychological distress and anxiety).
Applications may target development of evidence-based practices, behavioral health science interventions and surveillance, and identification of psychosocial patient outcomes.
Studies involving animal use are not appropriate for the Behavioral Health Science Award.
If animal studies are proposed, the application may be withdrawn.
The critical components of this award mechanism are:
· Impact:
The Behavioral Health Science Award is intended to support research that demonstrates the potential to have a major impact on patient outcomes, especially during the three stages of survivorship (acute, extended, and/or permanent).
The proposed study must demonstrate how the research will transform behavioral health outcomes related to at least one of the FY22 PRCRP Topic Areas.
Research should challenge paradigms with respect to impact on patient care and outcomes.
Proposed projects may include translational or clinical research, including pilot clinical trials.
Impactful research will accelerate the movement of promising ideas into clinical applications and advance the behavioral health science in the area of survivorship.
· Study Design:
Applications should clearly articulate the chosen design of the study.
Studies entailing retrospective or prospective recruitment should define the type of architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses).
Study populations should be clearly defined.
The rationale should support the chosen study design with statistical evaluation to back the design.
Questionnaires should be described in sufficient detail to justify interpretation of potential results.
Research involving animal studies is not considered appropriate for the Behavioral Health Science Award.
While not prohibited, strong justification must be included in the project narrative for any animal studies proposed.
· Preliminary Data:
The Behavioral Health Science Award will require preliminary data for all studies that propose the active (prospective) recruitment of human subjects for pilot clinical trials.
Studies not proposing active recruitment of human subjects are not required to present preliminary data, but should be supported by sound reasoning and relevant literature.
· Patient Advocate Participation:
Applications to the Behavioral Health Science Award funding opportunity are required to include patient advocates.
The research team must include at least one cancer patient advocate who will be integral throughout the planning and implementation of the research project.
The patient advocate will be a person living with cancer; a person previously diagnosed with/treated for cancer but who now has no evidence of disease; or a family member or caretaker of someone with cancer.
As a lay representative, the patient advocate should be active in a cancer advocacy organization.
The patient advocate should be involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project.
Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings.
The role of the patient advocate should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, cancer.
At least one patient advocate should have a high level of knowledge of current cancer issues in the selected FY22 PRCRP Topic Area(s).
Studies
must address one or more of these critical issues in at least one of the FY22 PRCRP Topic Areas.
The overall intention of the Behavioral Health Science Award is to advance behavioral health cancer science and fill gaps in the understanding of survivorship, including investigations into the psychological health and well-being of those affected by cancer (e.g., patients, family members).
This may include investigations into studies that improve mental health and/or cancer-related outcomes in defined populations.
Studies also may assess the relationship(s) between behavioral and social functioning in relation to cancer initiation, progression, detection, treatment, and rehabilitation.
Applications may propose behavioral science that examines quality-of-life studies, decision-making and/or cognitive function research, development and testing of educational interventions, and symptom management (e.g., toxicity of treatment, palliative care, psychological distress and anxiety).
Applications may target development of evidence-based practices, behavioral health science interventions and surveillance, and identification of psychosocial patient outcomes.
Studies involving animal use are not appropriate for the Behavioral Health Science Award.
If animal studies are proposed, the application may be withdrawn.
The critical components of this award mechanism are:
· Impact:
The Behavioral Health Science Award is intended to support research that demonstrates the potential to have a major impact on patient outcomes, especially during the three stages of survivorship (acute, extended, and/or permanent).
The proposed study must demonstrate how the research will transform behavioral health outcomes related to at least one of the FY22 PRCRP Topic Areas.
Research should challenge paradigms with respect to impact on patient care and outcomes.
Proposed projects may include translational or clinical research, including pilot clinical trials.
Impactful research will accelerate the movement of promising ideas into clinical applications and advance the behavioral health science in the area of survivorship.
· Study Design:
Applications should clearly articulate the chosen design of the study.
Studies entailing retrospective or prospective recruitment should define the type of architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses).
Study populations should be clearly defined.
The rationale should support the chosen study design with statistical evaluation to back the design.
Questionnaires should be described in sufficient detail to justify interpretation of potential results.
Research involving animal studies is not considered appropriate for the Behavioral Health Science Award.
While not prohibited, strong justification must be included in the project narrative for any animal studies proposed.
· Preliminary Data:
The Behavioral Health Science Award will require preliminary data for all studies that propose the active (prospective) recruitment of human subjects for pilot clinical trials.
Studies not proposing active recruitment of human subjects are not required to present preliminary data, but should be supported by sound reasoning and relevant literature.
· Patient Advocate Participation:
Applications to the Behavioral Health Science Award funding opportunity are required to include patient advocates.
The research team must include at least one cancer patient advocate who will be integral throughout the planning and implementation of the research project.
The patient advocate will be a person living with cancer; a person previously diagnosed with/treated for cancer but who now has no evidence of disease; or a family member or caretaker of someone with cancer.
As a lay representative, the patient advocate should be active in a cancer advocacy organization.
The patient advocate should be involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project.
Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings.
The role of the patient advocate should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, cancer.
At least one patient advocate should have a high level of knowledge of current cancer issues in the selected FY22 PRCRP Topic Area(s).
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
https://www.hud.gov/program_offices/spm/gmomgmt/grantsinfo/fundingopps
Additional Information of Eligibility:
1.
Eligible Applicants.
For Renewal Applicants - PHAs (including MTW PHAs) currently administering an FSS program that have met all funding requirements outlined in prior year Notice of Awards and Grant Agreements and the Terms and Conditions therein, see Appendix C. You will only be eligible for Renewal funding if you were funded under any of the FY 2021, FY 2020, and/or FY 2019 FSS NOFOs Please Note – PHAs that have repositioned all of their Public Housing stock in which FSS participants resided and do not serve HCV FSS participants are not eligible to apply for funding under this NOFO as renewal applicants, as, when their current funding ends, they will no longer meet the definition of “currently administering an FSS program.” For example, your PHA has 60 PH units and no vouchers. You have 18 FSS participants. You reposition all the PH units where those 18 FSS participants live (for instance, you use RAD to convert all your family units to PBRA and all your FSS participants lived in family units.) Due to the RAD notice, you can continue using your FY21 FSS NOFO funding through 12/31/22. However, you no longer have a PH FSS program and you do not serve HCV FSS participants. After 12/31/22, your PHA will no longer administer an FSS program (even if you, as the PBRA owner, are serving those RAD-affected FSS participants).
Thus, you are not eligible for renewal funding under this FY22 NOFO.
For New Applicants – PHAs that have not been funded for an FSS grant in any of the last 3 years (FY21, FY20, FY19) and PBRA owners already implementing or wishing to implement an FSS program are eligible for funding under Category 4 of this NOFO.
Individuals, foreign entities, and sole proprietorship organizations are not eligible to compete for, or receive, awards made under this announcement.
Full Opportunity Web Address:
https://www.hud.gov/program_offices/spm/gmomgmt/grantsinfo/fundingopps
Contact:
Agency Email Description:
CDMRP Help Desk
Agency Email:
Date Posted:
2022-08-04
Application Due Date:
Archive Date:
2022-11-19
Social Entrepreneurship
Spotlight
This Social Innovation Helps Prevent Bed Sores in Wheelchair Users
Co-founders William Mann and David Mravyan devised the Sensimat during a mandatory project for their MBA at the Richard Ivey School of Business in Canada. Sensimat is a device that helps manage and assess pressure among wheelchair users.
Learn How to Identify and Avoid Grant Scams
